Related references
Note: Only part of the references are listed.The Association of Low Molecular Weight Heparin Use and In-hospital Mortality Among Patients Hospitalized with COVID-19
Lan Shen et al.
CARDIOVASCULAR DRUGS AND THERAPY (2022)
Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register
Daniela Poli et al.
INTERNAL AND EMERGENCY MEDICINE (2022)
Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19 A Randomized Clinical Trial
Jeffrey S. Berger et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial
Eduardo Ramacciotti et al.
LANCET (2022)
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Peter W. Horby et al.
LANCET (2022)
Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial
Behnood Bikdeli et al.
THROMBOSIS AND HAEMOSTASIS (2022)
A prospective study of the impact of glycaemic status on clinical outcomes and anti-SARS-CoV-2 antibody responses among patients with predominantly non-severe COVID-19
David Tak Wai Lui et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2022)
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19 A Randomized Clinical Trial
Charlotte A. Bradbury et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Low molecular weight heparin is useful in adult COVID-19 inpatients. Experience during the first Spanish wave: observational study
Jose Ramon Gonzalez-Porras et al.
SAO PAULO MEDICAL JOURNAL (2022)
The association between anticoagulation and adverse outcomes after a positive SARS-CoV-2 test among older outpatients: A population-based cohort study
Husam Abdel-Qadir et al.
THROMBOSIS RESEARCH (2022)
Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH
Alex C. Spyropoulos et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)
Association of anticoagulation dose and survival in hospitalized COVID-19 patients: A retrospective propensity score-weighted analysis
Filip Ionescu et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2021)
Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis
Matthew L. Meizlish et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study
David Pereyra et al.
CARDIOVASCULAR RESEARCH (2021)
Direct oral anticoagulant use and risk of severe COVID-19
B. Flam et al.
JOURNAL OF INTERNAL MEDICINE (2021)
Prevalence and Predictors of Venous Thromboembolism or Mortality in Hospitalized COVID-19 Patients
Stuart L. Cohen et al.
THROMBOSIS AND HAEMOSTASIS (2021)
Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: the Multicenter Italian CORIST Study *
Augusto Di Castelnuovo et al.
THROMBOSIS AND HAEMOSTASIS (2021)
Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19 The ACTIV-4B Randomized Clinical Trial
Jean M. Connors et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: population-based cohort study
Angel Y. S. Wong et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration
Thomas F. Osborne et al.
PLOS ONE (2021)
Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial
Alejandro J. Gonzalez-Ochoa et al.
THROMBOSIS AND HAEMOSTASIS (2021)
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19 The HEP-COVID Randomized Clinical Trial
Alex C. Spyropoulos et al.
JAMA INTERNAL MEDICINE (2021)
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit The INSPIRATION Randomized Clinical Trial
Parham Sadeghipour et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry
Dimitrios Giannis et al.
BLOOD (2021)
Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial
Usha S. Perepu et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial
Renato D. Lopes et al.
LANCET (2021)
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
Patrick R. Lawler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
Ewan C. Goligher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
Dawn O. Kleindorfer et al.
STROKE (2021)
Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes
Jose Miguel Rivera-Caravaca et al.
THROMBOSIS RESEARCH (2021)
Randomized trials of therapeutic heparin for COVID-19: A meta-analysis
Michelle Sholzberg et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2021)
Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients
Sameh M. Hozayen et al.
ECLINICALMEDICINE (2021)
Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19
Alex C. Spyropoulos et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
ISTH interim guidance on recognition and management of coagulopathy in COVID-19
Jecko Thachil et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients
Alex C. Spyropoulos et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)
Anna Cristina Bertoldi Lemos et al.
THROMBOSIS RESEARCH (2020)
Thromboembolic Complications in Patients With COVID-19
Gregory Piazza et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis
Stephan Nopp et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)
American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients
Holger J. Schunemann et al.
BLOOD ADVANCES (2018)
Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH
S. Kaatz et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
ACCF/AHA Clinical Practice Guideline Methodology Summit Report A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Alice K. Jacobs et al.
CIRCULATION (2013)
Dalteparin versus Unfractionated Heparin in Critically Ill Patients
Deborah Cook et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score
S. Barbar et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Identifying acutely ill medical patients requiring thromboprophylaxis
P Chopard et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
S Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients
A Leizorovicz et al.
CIRCULATION (2004)